No­var­tis preps Kisqali for FDA; Ven­tyx cuts 20% of work­ers; Keytru­da plus Lenvi­ma hits PhI­II set­back

Plus news about Rigel Phar­ma­ceu­ti­cals col­lab­o­rat­ing with MD An­der­son.

No­var­tis up­dates PhI­II da­ta for Kisqali: The com­pa­ny has al­ready filed the NA­TALEE da­ta with the EMA and will sub­mit up­dat­ed da­ta to the FDA by the end of the year. Kisqali is cur­rent­ly ap­proved in the metasta­t­ic dis­ease set­ting.

Ven­tyx slash­es 20% of work­force: The com­pa­ny end­ed Sep­tem­ber with 99 full-time em­ploy­ees and around $56 mil­lion in cash. The move is ex­pect­ed to cost the biotech $2 mil­lion in sev­er­ance and re­lat­ed em­ploy­ee ben­e­fits. In No­vem­ber, the com­pa­ny cut its pso­ri­a­sis pro­gram on the back of lack­lus­ter Phase II re­sults, prompt­ing a steep drop in its share price $VTYX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER